Genmab wins international biotech award for top performance  

2005.02.28
Copenhagen based biotech company Genmab has been awarded the James D. Watson Helix Award for top performance by the BIO and Long Island Life Sciences Initiative

Copenhagen based biotech company Genmab has been awarded the James D. Watson Helix Award for top performance in the international biotech category, by the Biotechnology Industry Organization (BIO) and the Long Island Life Sciences Initiative. Winners were selected by peer vote, and the award was presented February 24 at the BIO CEO and Investor Conference in New York.

 

The James D. Watson Helix Award honours leadership in three areas: scientific innovation, company growth and corporate citizenship. Genmab received the award for its significant advances in 2004, including presentation of positive data from all five of its clinical programmes. Financially, the company raised approx. USD 100 mn (DKK 542 mn), and saw its share value increase by 96% in 2004. The news is reported by financial daily newspaper Børsen and on Genmab's website.

 

Genmab is headquartered in Copenhagen and has operations in Utrecht, Holland and Princeton, New Jersey. Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis.

 

James D. Watson, together with Francis Crick, discovered the double helix structure of DNA which they announced to the world in 1953. The Cambridge-based pair were subsequently awarded the Nobel Prize for their famous achievement.

 

Link > Genmab 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×